A case report of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein tumor embolism

Tanoue, Yusuke; Tanaka, Nobutaka; Suzuki, Yoshio; Hata, Shoujirou; Yokota, Aya

doi:10.3748/wjg.15.248

Cited by 8 publications

(3 citation statements)

References 11 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These younger patients often present with advanced-stage disease more commonly than older patients [30] for reasons that are not clear. As described, endocrine cell carcinoma of the colon is rare, and ascites is associated with less than 10% of colon cancer, with both features associated with a poor prognosis [31]. It remains to be determined if FGFR2 amplification or overexpression are associated with the uncommon histological subsets of ascites or endocrine differentiation.…”

Section: Discussionmentioning

confidence: 96%

FGFR2 Is Amplified in the NCI-H716 Colorectal Cancer Cell Line and Is Required for Growth and Survival

et al. 2014

View full text Add to dashboard Cite

Aberrant kinase activation resulting from mutation, amplification, or translocation can drive growth and survival in a subset of human cancer. FGFR2 is amplified in breast and gastric cancer, and we report here the first characterization of FGFR2 gene amplification in colorectal cancer in the NCI-H716 colorectal cancer cell line. FGFR2 is highly expressed and activated in NCI-H716 cells, and FGFR selective small molecule inhibitors or FGFR2 shRNA strongly inhibited cell viability in vitro, indicating “addiction” of NCI-H716 cells to FGFR2. NCI-H716 growth in a xenograft model was also inhibited by an FGFR small molecule inhibitor. FGFR2 was required for activation of multiple downstream signaling proteins including AKT, ERK, S6RP and NFKB. Inhibition of downstream kinases such as AKT or ERK alone had modest effects on proliferation, whereas combined inhibition of AKT and ERK signaling resulted in a loss of viability similar to FGFR2 inhibition. We identified elevated FGFR2 expression in a small subset of primary colorectal cancer, however FGFR2 amplification was not observed. Although FGFR2 amplification is not common in primary colon cancer or lymph node and liver metastases, other subsets of colorectal cancer such as ascites, from which the NCI-H716 cell line was derived, have yet to be tested. These results suggest that emerging FGFR inhibitor therapeutics may have efficacy in a subset of colon cancer driven by FGFR2 amplification.

show abstract

Section: Discussionmentioning

confidence: 96%

FGFR2 Is Amplified in the NCI-H716 Colorectal Cancer Cell Line and Is Required for Growth and Survival

et al. 2014

View full text Add to dashboard Cite

show abstract

“…21 of non-ionic contrast agent (Iopamiron 300; Bayer-Schering, Berlin, Germany) was performed as follows: half of the contrast agent was injected at a rate of 0.5 ml s 21 , after the end of the first half of the injection, there was a pause of 1 min and 30 s, and then, the remaining half of the contrast agent was injected at a rate of 1.5 ml s 21 . Enhanced images from the chest to the pelvis were subsequently obtained without interval.…”

Section: Intravenous Injection Of 2 ML Kgmentioning

confidence: 99%

“…Several reports have described CT appearances of tumour invasion in large veins such as the vena cava and the portal vein and their tributaries. 20,21 However, only one report described CT-pathological correlation of venous invasion in small-or medium-sized veins. 22 In that report, the interobserver agreement for CT detection of venous invasion was poor, and the architecture of the vessel wall did not seem to be confirmed pathologically by additional special staining such as Elastica van Gieson stain (EVG).…”

mentioning

confidence: 99%

Local massive venous invasion in colorectal cancer: CT-pathological correlation and its clinical implication

Nakajima¹,

Aoki²,

Sakurai³

et al. 2015

BJR

View full text Add to dashboard Cite

Objective: To identify CT findings of massive venous invasion (MVI) in colorectal cancer, compare them to pathological findings and evaluate its clinical implications. Methods: Among 423 patients who received surgical resection of colorectal cancer, pre-operative CT of 26 patients (15 males, 11 females; mean age, 63.0 6 12.1 years) with histopathologially proven MVI and 26 patients (14 males, 12 females; mean age, 71.1 6 9.6 years) with histopathologically proven lymph node (LN) metastases were reviewed and compared with histopathological findings. We evaluated CT detectability of MVI and the morphologic differences between MVI and LN metastasis. All cases were followed up for at least 6 months after surgery. Results: Pre-operative CT correctly diagnosed only one case as tumour thrombus. 9 lesions were not detected on CT, and others were misdiagnosed pre-operatively as regional LN metastasis (14 cases) and juxtatumoural abscess (2 cases). After reviewing these cases, MVIs were identifiable in 20 of 26 cases. MVI was depicted on CT as nodules (oval, lobulated), abscess-like or intravenous tumour thrombus. MVI was significantly larger than LN metastasis (p , 0.05), while contrast enhancement was significantly lower (p , 0.05), and MVI often had an enhanced rim. Ten patients had synchronous metastases, and six patients had metachronous distant metastases within 5 years. Conclusion: Many cases of MVI were distinguishable from LN metastases on pre-operative CT of colorectal cancer, but their appearances were varied, reflecting their histopathological behaviours. The distant metastatic rate was much higher in cases with MVI. Advances in knowledge: Radiologists should be aware of CT findings of MVI in colorectal cancer as a sentinel sign of distant metastasis.Radiological staging is indispensable for the management of colorectal cancer. The TNM classification is a worldwide method for the staging.

show abstract

Colorectal cancer with venous tumor thrombosis

Otani

Ishihara

Hata

et al. 2018

Asian Journal of Surgery

View full text Add to dashboard Cite

Colorectal cancer is seldom accompanied by venous tumor thrombosis, and little is known about the features of venous tumor thrombosis in colorectal cancer. However, some reports show that colorectal cancer patients can develop venous tumor thrombosis and warn clinicians not to overlook this complication. In this report, we perform a review of 43 previously reported cases and investigate the characteristics of colorectal cancer accompanied by venous tumor thrombosis. The histological type of more than half of the cases was moderately differentiated adenocarcinoma, which is known to be aggressive. Among 41 cases with available data on liver metastasis, eight patients had synchronous liver metastasis, and liver metastatic recurrence after surgical resection was indicated in 10 patients. This liver metastatic rate was high compared to general colorectal cancer. However, 11 of 43 patients with venous tumor thrombosis could survive for more than 2 years after the diagnosis, although five of the 11 patients had liver metastasis. A long survival can be anticipated for patients following complete tumor resection and adjuvant chemotherapy. A greater accumulation of cases will help elucidate the characteristics of colorectal cancer with venous tumor thrombosis and improve the treatment strategy.

show abstract

A case report of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein tumor embolism

Cited by 8 publications

References 11 publications

FGFR2 Is Amplified in the NCI-H716 Colorectal Cancer Cell Line and Is Required for Growth and Survival

FGFR2 Is Amplified in the NCI-H716 Colorectal Cancer Cell Line and Is Required for Growth and Survival

Local massive venous invasion in colorectal cancer: CT-pathological correlation and its clinical implication

Colorectal cancer with venous tumor thrombosis

Contact Info

Product

Resources

About